A Phase II Adjuvant Study of GRANITE-001 in High-Risk Localized Tumors
Latest Information Update: 12 Aug 2021
At a glance
- Drugs GRANITE 001 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Gritstone bio
Most Recent Events
- 05 Aug 2021 According to a Gritstone bio media release, the company expects to initiate this study in the first half of 2022.
- 06 May 2021 According to a Gritstone bio media release, the company expects to initiate this study in the second half of 2021.
- 24 Jun 2020 According to a Gritstone Oncology media release, the company announced that the company will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET where phase 2 study plans will also be discussed.